Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying

Published 03/01/2024, 12:11
Updated 03/01/2024, 13:40
© Reuters.  Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Airship AI Holdings

  • The Trade: Airship AI Holdings, Inc. (NASDAQ: AISP) Director, CEO and Chairman of the BOD Victor Huang acquired a total of 60,000 shares an average price of $1.92. To acquire these shares, it cost around $114,917.
  • What’s Happening: Airship AI recently started delivery of $10.9 million U.S. government contracts for advanced video and sensor management.
  • What Airship AI Holdings Does: Airship AI Holdings Inc is a U.S.-owned and operated technology company. Airship AI is an AI-driven video, sensor and data management surveillance platform that improves public safety and operational efficiency for public sector and commercial customers by providing predictive analysis of events before it occur and meaningful intelligence to decision makers.
Lineage Cell Therapeutics
  • The Trade: Lineage Cell Therapeutics, Inc. (NYSE: LCTX) Director Anula Jayasuriya acquired a total of 10,000 shares at at an average price of $1.09. To acquire these shares, it cost around $10,900.
  • What’s Happening: Lineage Cell Therapeutics, last month, submitted investigational new drug amendment to the FDA for OPC1 for the treatment of chronic and subacute spinal cord injury.
  • What Lineage Cell Therapeutics Does: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Globalstar

  • The Trade: Globalstar, Inc. (NYSE: GSAT) Director James F Lynch acquired a total of 500,000 shares at an average price of $1.93. The insider spent around $963,700 to buy those shares.
  • What’s Happening: On Nov. 2, Globalstar reported third-quarter FY23 sales growth of 53% year-on-year to $57.7 million.
  • What Globalstar Does: Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services.
Longeveron
  • The Trade: Longeveron Inc. (NASDAQ: LGVN) Director Khoso Baluch acquired a total of 10,000 shares at an average price of $1.43. The insider spent around 14,257 to buy those shares.
  • What’s Happening: Longeveron recently announced a $2.36 million registered direct offering priced at-the-market under Nasdaq rules.
  • What Longeveron Does: Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions.

Don’t forget to check out our premarket coverage here

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.